1 recruiting, 1 withdrawn. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow oplunofusp: new trials by email Literature Review of oplunofusp trials Research Report on oplunofusp
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DAS181 for STOP COVID-19 DAS181, Placebo - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Ansun Biopharma, Inc. | 2020-07-25 | 2020-08-11 | |
| Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study DAS181, Placebo, DAS181 COVID-19 - Lower Respiratory Tract Infection, Parainfluenza | Phase 3 | Recruiting | Ansun Biopharma, Inc. | 274 | 2019-05-23 | 2026-06-23 |
COVID-19 (2) · Coronavirus Infections (2) · Hypoxia (1) · Paramyxoviridae Infections (1)
Australia (1) · China (1) · Italy (1) · South Korea (1) · Taiwan (1) · United States (1)
Jennifer Ho, MD, PhD (1) · Ronald B Moss, MD (1)
2018 (1)